Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNXNASDAQ:CVACNASDAQ:SRRKNASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$33.52+0.4%$32.14$24.10▼$62.53$3.14B0.37859,331 shs652,903 shsCVACCureVac$3.40-4.2%$3.05$2.37▼$5.28$762.75M2.48800,378 shs399,662 shsSRRKScholar Rock$32.76-0.5%$32.33$6.76▼$46.98$3.11B0.561.26 million shs984,136 shsVKTXViking Therapeutics$28.61-0.9%$26.16$18.92▼$81.86$3.21B0.844.09 million shs3.45 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+0.24%+3.15%-0.45%-17.06%-23.80%CVACCureVac+0.57%+11.46%+28.16%-7.07%+40.87%SRRKScholar Rock+0.43%+0.98%+2.36%-18.54%+124.34%VKTXViking Therapeutics+3.33%+11.73%+19.54%-14.31%-63.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRNXCrinetics Pharmaceuticals3.655 of 5 stars3.51.00.03.73.12.50.0CVACCureVac3.9524 of 5 stars3.52.00.04.82.50.01.3SRRKScholar Rock4.049 of 5 stars3.50.00.04.43.43.30.6VKTXViking Therapeutics4.4904 of 5 stars4.52.00.04.72.33.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.92Moderate Buy$73.00117.78% UpsideCVACCureVac 3.00Buy$14.00311.76% UpsideSRRKScholar Rock 3.00Buy$42.6730.24% UpsideVKTXViking Therapeutics 3.00Buy$87.15204.63% UpsideCurrent Analyst Ratings BreakdownLatest CVAC, CRNX, SRRK, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/8/2025VKTXViking TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$30.003/26/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.003/25/2025CRNXCrinetics PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.003/25/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$1.04M3,020.64N/AN/A$8.07 per share4.15CVACCureVac$535.18M1.43N/AN/A$2.50 per share1.36SRRKScholar Rock$33.19M93.63N/AN/A$3.12 per share10.50VKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$214.53M-$3.71N/AN/AN/AN/A-36.12%-31.89%5/8/2025 (Estimated)CVACCureVac-$281.58M$0.826.18N/AN/A20.72%21.98%15.72%5/22/2025 (Estimated)SRRKScholar Rock-$165.79M-$2.45N/AN/AN/AN/A-145.60%-91.83%5/6/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%N/ALatest CVAC, CRNX, SRRK, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025CVACCureVac-$0.16N/AN/AN/A$4.27 millionN/A5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99N/AN/AN/A$0.10 millionN/A5/6/2025Q1 2025SRRKScholar Rock-$0.63N/AN/AN/AN/AN/A4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/A4/10/2025Q4 2024CVACCureVac-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million2/27/2025Q4 2024CRNXCrinetics Pharmaceuticals-$0.92-$0.88+$0.04-$0.88$0.73 millionN/A2/5/2025Q4 2024VKTXViking Therapeutics-$0.27-$0.32-$0.05-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A16.3916.38CVACCureVac0.056.206.19SRRKScholar Rock0.633.883.88VKTXViking TherapeuticsN/A36.4736.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%CVACCureVac17.26%SRRKScholar Rock91.08%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals6.00%CVACCureVac2.15%SRRKScholar Rock13.30%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals21093.63 million87.17 millionOptionableCVACCureVac880224.34 million219.07 millionOptionableSRRKScholar Rock14094.86 million75.64 millionOptionableVKTXViking Therapeutics20112.29 million106.20 millionOptionableCVAC, CRNX, SRRK, and VKTX HeadlinesRecent News About These CompaniesViking Therapeutics (NASDAQ:VKTX) Shares Gap Up - What's Next?May 1 at 12:18 PM | marketbeat.com1 Beaten-Down Stock to Buy and Hold for 10 YearsMay 1 at 5:47 AM | fool.comStifel Financial Corp Increases Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 1 at 4:54 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Rating Increased to Strong-Buy at Cantor FitzgeraldMay 1 at 1:37 AM | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Coverage Initiated by Analysts at Cantor FitzgeraldApril 30 at 5:30 PM | marketbeat.comTruist Financial Reiterates Buy Rating for Viking Therapeutics (NASDAQ:VKTX)April 30 at 10:14 AM | marketbeat.comGilder Gagnon Howe & Co. LLC Takes $671,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)April 30 at 6:13 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Voya Investment Management LLCApril 30 at 5:39 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Barclays PLCApril 30 at 3:49 AM | marketbeat.comPrediction: Pfizer's Loss May Be Viking Therapeutics' GainApril 30 at 3:15 AM | fool.comViking Therapeutics (NASDAQ:VKTX) Receives Buy Rating from Truist FinancialApril 30 at 2:53 AM | americanbankingnews.comCantor Fitzgerald Initiates Coverage of Viking Therapeutics (VKTX) with Overweight RecommendationApril 30 at 1:58 AM | msn.comWhy Viking Therapeutics Stock Popped Again TodayApril 29 at 12:24 PM | fool.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Artia Global Partners LPApril 29 at 7:00 AM | marketbeat.comAquatic Capital Management LLC Purchases New Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)April 29 at 6:34 AM | marketbeat.comWilliam Blair Analysts Lower Earnings Estimates for VKTXApril 29 at 1:17 AM | americanbankingnews.comQ2 EPS Forecast for Viking Therapeutics Decreased by AnalystApril 29 at 1:17 AM | americanbankingnews.comQ2 EPS Forecast for Viking Therapeutics Lowered by AnalystApril 29 at 1:16 AM | marketbeat.comHC Wainwright Has Pessimistic Outlook of VKTX Q2 EarningsApril 29 at 1:16 AM | marketbeat.comLeerink Partnrs Has Negative Estimate for VKTX Q2 EarningsApril 29 at 1:16 AM | marketbeat.comWilliam Blair Issues Negative Estimate for VKTX EarningsApril 29 at 1:16 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonViking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsViking Therapeutics Stock May Struggle After As-Expected ReportBy Chris Markoch | April 25, 2025View Viking Therapeutics Stock May Struggle After As-Expected ReportCVAC, CRNX, SRRK, and VKTX Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$33.52 +0.13 (+0.39%) Closing price 04:00 PM EasternExtended Trading$33.76 +0.24 (+0.73%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.CureVac NASDAQ:CVAC$3.40 -0.15 (-4.23%) Closing price 04:00 PM EasternExtended Trading$3.55 +0.15 (+4.41%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Scholar Rock NASDAQ:SRRK$32.76 -0.15 (-0.46%) Closing price 04:00 PM EasternExtended Trading$32.76 0.00 (-0.02%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Viking Therapeutics NASDAQ:VKTX$28.61 -0.26 (-0.90%) Closing price 04:00 PM EasternExtended Trading$28.69 +0.08 (+0.29%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
